Our mission and daily commitment is to enable accessible and affordable healthcare by eliminating the difficult task of running and analyzing reports through data and analytics automation.
With the Delta variant raging across New South Wales and Victoria, health services are stretched and strained. Behind the scenes is a fearful, anxious and overburdened workforce.
In the next few months, the health workforce will care for many more...
Let's look at the most significant digital healthcare transformation in the healthcare industry.
Wildfires burning in the western U.S. are sending smoke into communities far from the fires themselves, creating hazardous air for days or weeks at a time. A lot of people are wondering: What does breathing all that smoke do...
Thanks to the efforts of scientists, healthcare workers and trial participants around the world, a number of COVID-19 vaccines have now been authorised for general use. But while millions have been given a jab, billions still need to be vaccinated. We...
With new, more infectious variants of COVID-19 detected around the world, and at New Zealand’s border, the risk of further level 3 or 4 lockdowns is increased if those viruses get into the community.
These include a variant called B.1.1.7...
For most people, infection with SARS-CoV-2 – the virus that causes COVID-19 – leads to mild, short-term symptoms, acute respiratory illness, or possibly no symptoms at all. But some people have long-lasting symptoms after their infection – this has...
Vaccines for COVID-19 are now being rolled out, but in some parts of the world, this good news has been tempered by the emergence of new, potentially more infectious strains of the virus. Exactly how the pandemic will evolve has become...
There was – rightfully – a lot of excitement when Pfizer and BioNTech announced interim results from their COVID vaccine trial. The vaccine, called BNT162b2, was reported to have an “efficacy rate above 90%”. This was soon translated in the press to...
Only days after the federal government announced a A$1.7 billion vaccine deal to roll out COVID-19 vaccines to Australians in 2021, one of the two candidates has halted its phase 3 trials after a participant became ill.
The AZD1222 vaccine,...
